Lucid Diagnostics Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.7M | $4.3M | $2.4M | $377,000 | $500,000 |
| Cost of revenue | $6.7M | $7.1M | — | $100.0M | $585,000 |
| Gross profit | — | — | — | $377,000 | $500,000 |
| Selling, general & administrative | — | — | — | — | $21,000 |
| Research and development | $5.7M | $6.0M | $7.3M | $11.3M | $9.3M |
| Operating expenses | — | $50.4M | $50.9M | $56.6M | $27.9M |
| Operating income | -$49.6M | -$46.1M | -$48.5M | -$56.3M | -$27.4M |
| Interest expense | $22,000 | $26,000 | $416,000 | $8,000 | — |
| Pretax income | -$58.0M | -$45.5M | -$52.7M | -$56.2M | -$28.1M |
| Income tax expense | $0 | $0 | — | — | — |
| Net income | -$58.0M | -$45.5M | -$52.7M | -$56.2M | -$28.1M |
| Balance Sheet | |||||
| Cash and equivalents | — | $22.4M | $18.9M | $22.5M | $53.7M |
| Current assets | $37.5M | $25.1M | $22.1M | $24.4M | $57.3M |
| Total assets | $40.4M | $30.7M | $27.3M | $32.5M | $59.0M |
| Current liabilities | $28.6M | $23.5M | $29.4M | $8.4M | $4.3M |
| Total liabilities | $29.5M | $25.3M | $29.6M | $9.5M | $4.3M |
| Stockholders' equity | $10.9M | $5.4M | -$2.3M | $23.0M | $54.7M |
| Cash Flow Statement | |||||
| Cash from operations | -$46.5M | -$44.1M | -$32.8M | -$29.7M | -$17.7M |
| Depreciation and amortization | $872,000 | $1.2M | $2.5M | $1.9M | $4,000 |
| Stock-based compensation | $4.5M | $4.2M | $5.8M | $13.9M | $9.1M |
| Capital expenditure | $197,000 | $296,000 | — | $3.2M | $862,000 |
| Free cash flow | -$46.7M | -$44.4M | — | -$32.9M | -$18.5M |
Shares outstanding 203.1M · Free float 65.9%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.